Lv31
286 积分 2021-03-05 加入
Assessing adverse event burden in chronic lymphocytic leukemia treatment regimens: what’s best for patient quality of life?
1小时前
求助中
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
29天前
已完结
Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges
29天前
已完结
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
1个月前
已完结
Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment
1个月前
已完结
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
1个月前
已完结
Emerging role of EZH2 in solid tumor metastasis
3个月前
已完结
Establishment and Culture of Leukemia–Lymphoma Cell Lines
4个月前
已完结
Regulatory Toxicology and Pharmacology New limits proposed for the management of non-mutagenic impurities
4个月前
已完结
Deriving acceptable limits for non-mutagenic impurities in medicinal products – Durational adjustments
4个月前
已完结
皖公网安备34019202002308
